Whether developing a new drug or medical device, designing and running clinical trials can be daunting. How drugs and devices are developed differ dramatically. Study design and regulatory pathways differ; requirements for study sites, end users, training, endpoints and follow up are all variables. This paper examines the key differences and how those impact clinical development with a focus on the US regulatory environment.
IN CASE YOU MISSED IT
- Non-insulin, basal CGM use exceeds analysts’ expectations, Dexcom and Abbott to benefit
- Eli Lilly acquires new injectable medicine manufacturing plant
- Concept Medical enrolls first patient in drug-coated balloon study
- Kindeva Drug Delivery has a new COO
- Fresenius Kabi has a Class I recall of Ivenix Infusion System software